Filing Flows › Mangoceuticals (MGRX) › Q4 2025
Mangoceuticals (MGRX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Apr 1, 2026
Mangoceuticals (MGRX) reported revenue of $94K for the fourth quarter 2025 (Q4 2025), -10% from a year earlier and +12% from the quarter before. Operating margin was -389.7%.
Mangoceuticals, Q4 2025: revenue $94K (-10% year over year), operating margin -389.7%, net loss $2.8M, operating cash flow −$1.1M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $94K | +12% | -10% |
| Operating profit | −$368K | — | — |
| Net earnings | −$2.8M | — | — |
| Operating cash flow | −$1.1M | — | — |
What changed
Revenue was $94K in Q4 2025, down 10% year over year and up 12% from the previous quarter.
Gross margin was 50.3%, down 25.8 points from Q4 2024. Operating costs exceeded revenue by $368K, an operating margin of -389.7%. Operating expenses fell 76% while revenue fell 10%. The quarter ended with a net loss of $2.8M, narrower than the previous quarter's $7.6M loss. Net interest and other expense of $2.4M was the main reason.
Operating cash flow was −$1.1M. Non-cash charges added back $568K of depreciation and amortization. Working capital and other items added $1.1M.
Questions
What was Mangoceuticals' revenue in the fourth quarter 2025?
Mangoceuticals (MGRX) reported revenue of $94K for the fourth quarter 2025 (Q4 2025), -10% from a year earlier and +12% from the quarter before.
Was Mangoceuticals profitable in the fourth quarter 2025?
Operating loss was $368K (-389.7% of revenue) and net loss $2.8M.
Source: Mangoceuticals 10-K on SEC EDGAR.